secwatch.observer — SEC 8-K summary
======================================

Issuer:     EVOME MEDICAL TECHNOLOGIES INC. (—)
CIK:        0001617765
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001062993-24-008068
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evome sells Simbex R&D unit to Riddell for $3.55M cash; proceeds cut acquisition debt
--------------------------------------------------------------------------------

- Sale price $3.55M (~$4.83M CAD) cash for Simbex LLC to EB Sports Corp (Riddell parent).
- Proceeds reduce Simbex senior debt by ~$824k and Biodex acquisition debt by ~$2.12M.
- Annual revenue to decline ~$6M but net income impact immaterial; balance sheet strengthened.
- CEO notes two consecutive quarters of positive Adjusted EBITDA; expects 'breakout' Q2 for Biodex.
- New products: RST (Reactive Step Trainer) launched Feb 2024; SpaceTek Knee planned late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617765/000106299324008068/0001062993-24-008068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617765/000106299324008068/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-24-008068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer